Introduction
Until now, there is no gold standard diagnostic test for pneumonia. Pneumonia diagnosis depends on a mixture of clinical, laboratory, and radiological criteria; clinical criteria include fever and signs of respiratory distress, the laboratory findings include leukocytosis and tracheal-aspirate cultures, and radiological clues represent the existence of pulmonary infiltrate on chest radiograph. All these criteria help in diagnosis of pneumonia [1] . In mechanically ventilated patients, fever, leukocytosis, and new pulmonary infiltrates are clues for diagnosis of ventilator-associated pneumonia (VAP) [2] . The problem is that the presentation of pneumonia is not typical in most patients, and this was the cause for many investigators to search for other diagnostic modalities with the intention of increasing the detection of patients with true pneumonia and moreover detection of type of pneumonia and help in proper choice of therapy [3, 4] .
The vast array of current biomarkers accessible to diagnose pneumonia and differentiate it from other diseases has conveyed a new era in medicine. Formerly, doctors had to trust on clinical findings and radiological prospects, leading to delay in treatment initiation, so biomarkers have enhanced both diagnosis and prognosis. In fact, biomarkers are to be applied only as an aide to diagnosis [5] . Preferably, an inflammatory biomarker should be the one that cannot be identified or whose value is very low in the absence of inflammation; it should increase its level with intensified inflammatory processes and should fall with resolving inflammation.
Quantification of exhaled nitric oxide (NO) had been explored for pneumonia diagnosis and showed conflicting results [6] [7] [8] . For pneumonia diagnosis, detection of the amount of exhaled NO was made via certain NO detectors that can sense activation of inducible NO of inflammatory cells from peripheral airways and alveolar tissue. Consequently, maneuvers such as slow exhalation method can measure its level in expiratory gas [9] . Fractional exhaled nitric oxide (FeNO) measurement in exhaled breath is a quantitative, bedside, noninvasive, rapid tool of measuring airway inflammation that offers trusted and immediate results for measurement of airway inflammation, including asthma and pneumonia [6] . Although FeNO measurement provides a promising tool for reflecting airway inflammation, there are no existing established reference guidelines for its measurement, correct technique, and interpretation of the test results [10] .
So, the aim of the current work is to study the relation between FeNO level in exhaled breath and pneumonia types, non-VAP [including community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and aspiration pneumonia (AsP)] and VAP as well as the relation to arterial oxygen tension (PaO 2 )/ FiO 2 ratio, clinical severity of pneumonia, and the extent of radiological affection.
Patients and methods
A prospective observational descriptive study was conducted in Mansoura University Children's Hospital in the period between April 2014 and May 2016. A fully informed consent was taken from the parents of each child before sharing in the study. A departmental and institutional ethical approval was obtained. A departmental and institutional ethical approval was obtained. This study included 88 cases: 32 with VAP (group 1) and 56 with non-VAP (20 patients with CAP as group 2, 24 with HAP as group 3, and 12 with AsP as group 4).
Inclusion criteria were as follows:
(1) Age from 5 to 17 years.
(2) Children with CAP, defined as 'the presence of clinical signs of pneumonia in a previously healthy child due to an infection that was acquired outside the hospital' [11] .
(3) Children with HAP, defined as 'pneumonia that develops at least 48 h after being admitted to the hospital and that was not present at the time of hospital admission' [12] . (4) Children with AsP, defined as 'soiling of the oropharyngeal, esophageal, or stomach contents into the lower respiratory tract leading to lung compromise' [13] . (5) Children in ICU on mechanical ventilation due to nonrespiratory causes and developed VAP, defined as 'a lung infection diagnosed in patients undergoing mechanical ventilation for at least 48 h.' The clinical and radiological criteria for the diagnosis of VAP were diagnosed as the NNIS and the CDC guidelines [2] .
Exclusion criteria were as follows:
(1) Patients with obstructive lung diseases (bronchial asthma, alpha 1 antitrypsin deficiency, cystic fibrosis, and bilateral bronchiectasis). All patients were subjected to measurement of exhaled NO, detection of pneumonia severity via modified PIRO (predisposition, insult, response, and organ dysfunction) score, chest radiography, C-reactive protein, total leukocytic count, and PaO 2 . Patients were followed up till hospital discharge to detect patients' survival.
Measurement of fractional exhaled nitric oxide
FeNO was measured on the first day of admission or once pneumonia is diagnosed. The technique of measurement was carried out according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines [14] , using a hand-held portable device, NO breath device, manufactured by Bedfont Scientific Ltd, England, 2011 (NO Breath, Bedfont, UK) ( Figure 1 ). The principle for detection of FeNO via this device is based on the electrochemical sensor technology. Any gas that can be electrochemically oxidized or reduced can also be detected by means of this electrochemical sensor [15] .
To perform the test, patients were seated in the upright position without a nose clip. Patients were then asked to inspire as deeply as possible for three seconds then were asked to expire through the device mouthpiece, keeping the ball in the flow indicator in the middle of a black band in the center of the tube. This was done to keep the rate of the expired air at a constant flow of 50 ml/s [16] .
To ensure a breath sample was taken at the correct flow rate, the monitor was held upright all the time during the test. Measurements were repeated after 10 min until two acceptable comparable values (±2.5 ppb for measurements <35 ppb and ±5% for measurements ≥35 ppb) were obtained (maximum three attempts) [15] . The mean of two adequate values for each patient was recorded for analysis.
Interpretation of FeNO levels was done according to ATS 2011 guidelines [8] as follows:
(1) FeNO less than 20 ppb: low (normal).
(2) FeNO 20-35 ppb: intermediate.
(3) FeNO more than 35 ppb: high.
Fractional exhaled nitric oxide measurement in ventilated patients
Based on the guidelines presented by ATS [17] and previous studies [15, 18, 19] , the patients who were exposed to mechanical ventilation could measure FeNO through the off-line method. Gas of 250 ml was collected in sterilized calibration syringe of spirometry. A 19-G, 12-inch catheter was placed inside endotracheal tube via closed system aspiration, then air was aspirated in expiratory phase and then the aspirated air was collected in a calibration syringe. The syringe was injected into FeNO analyzer along 12 s.
Modified PIRO score
This is a clinical score to assess the severity of pneumonia in children; modified PIRO (predisposition, insult, response, organ dysfunction) score involves the following 10 items: predisposition (include two items: age <6 months and associated comorbidity), insult [include three items: hypoxia (O2 saturation <90), hypotension (according to age), and bacteremia], response (include two items: multilobar pneumonia and complicated pneumonia), and organ dysfunction (include three items: renal failure, liver cell failure, and acute respiratory distress syndrome). Each item in the score will take 0 or 1 point according to absence or presence of the clinical feature, respectively. The total items in the score will range from 0 to 10 points. The association between the modified PIRO score and child mortality was assessed by classifying patients into four strata of risk: low risk of mortality (the patient had from 0 to 2 points), moderate risk (the patient got a score of 3 or 4 points), high risk (the patient got a score of 5 points or 6), and very high risk of mortality (from 7 to 10 points) [20] .
Scoring of chest radiograph images by the study radiologists
For the purposes of this study, two senior intensivists having expertise in interpreting pediatric chest radiographs reviewed the 88 chest radiographs of the pediatric patients.
Chest radiograph scoring [21] A five-point CXR scoring tool was used to record the severity of lung abnormalities No breath device.
nonparametric data, respectively. Linear regression analysis was used to detect data effect. For all the aforementioned statistical tests done, the threshold of significance is fixed at 5% level.
Results Table 1 demonstrates the demographic findings in the studied cases. Mean age was higher in HAP (9.67±3.62 years) followed by CAP (9.30±3.03 years), VAP (8.63 ±2.69 years, which was approximate to the total mean age of 8.86±3.02 years), and AsP (7.17±1.99 years). Females were much more affected than males in all studied groups, and in total cases, apart from AsP, which was much more in male. Outcome was promising as recovery rate was 94.3% in all studied cases. Mortality rate was higher in VAP cases rather than AsP followed by CAP. There were no statistically significant differences between all the studied groups. Table 2 describes the clinical, laboratory, and radiological considerations in the studied patients. Clinical parameters was presented in modified PIRO score. Very high modified PIRO score was predominant in VAP (62.5%), followed by CAP, AsP, and HAP (40, 33, and 20%, respectively). High modified PIRO score was approximate among the four groups, but was higher in VAP followed by HAP, AsP, and CAP (37, 33, 25, and 20%, respectively). Moderate modified PIRO score was seen in a lower percentage of all patients, being higher in HAP than CAP (41 and 35%, respectively). Moreover, low modified PIRO score was seen is lower number of patients, which prevailed in AsP (25%). Statistically significant difference was detected among the four groups in modified PIRO score. PaO 2 /FiO 2 ratio worsened in its level in AsP and VAP groups but showed greater levels in CAP and HAP groups. Statistically significant differences were detected among the four groups regarding PaO 2 /FiO 2 ratio.
Blood markers of inflammation showed nonsignificant differences. Total leukocytic count was higher in AsP and HAP (23.5 and 23.4×10 3 /ml, respectively) followed by CAP and VAP (21.3 and 20.8×10 3 /ml, respectively). On the contrary, C-reactive protein showed higher value in VAP and HAP (60 mg/l) followed by CAP and AsP (48 mg/l). Regarding FeNO level, higher levels in exhaled breath was detected in VAP followed by AsP then HAP and lastly CAP (37.6, 33.4, 31.9, and 29.1 ppb, respectively). Statistically significant differences were detected among the four groups regarding FeNO level.
Radiological grading of pneumonia was informative; grades III and IV showed higher percentage in total cases studied. VAP group showed higher percentage in grade V (43.75%) unlike CAP, which showed higher percentage in grade III (70%) as same as AsP (58.3%). However, HAP showed higher percentage in group IV. Statistically significant difference was detected (0.00).
In (Table 3) , correlations between FeNO level in the four studied groups and different clinical, laboratory, and radiological data were accomplished. The table shows statistically significant weak positive effect of modified PIRO score on FeNO level (Figure 2 ), unlike other factors, which showed nonsignificant correlations. Table 4 summarizes FeNO level in the studied cases in contrast to parameters implied. FeNO did not significantly vary with sex or radiological grades. FeNO level prevailed in survived cases in comparison with died cases but without statistically significant differences. FeNO level significantly Linear regression analysis of FeNO level and modified PIRO score in the studied patients. FeNO, fractional exhaled nitric oxide PIRO, predisposition, insult, response, and organ dysfunction. differed with modified PIRO score, showing direct proportional with increment of the score.
Discussion
Pneumonia has long been considered as one of the most common and grave infections in childhood, with an incidence of 35-40/1000 in children less than 5 years old, 20/1000 person-years in children 5-10 years old, and 10/1000 person-years in children more than 10 years old in Europe and North America [22] . Even though pneumonia-linked mortality is infrequent in developed countries, the scenario is diverse in developing countries, where pneumonia is one of the foremost causes of childhood mortality [23] . With progress in laboratory measures, biomarkers obtained allow great predictions for supporting critical decisions for pneumonia management. Remarkably, the prognostic and diagnostic utility of these biomarkers have been verified in both geriatric and pediatric infections.
FeNO is a bedside, rapid and noninvasive tool for evaluating inflammation of the airway in children.
Currently, different tools are available to measure FeNO level during exhalation [6, 15, 16] . The commercial handiness of portable devices encourages the use of FeNO quantification in the airway inflammatory diseases and pneumonia in children even in the daily practice in the outpatient clinics [24] . Although many perplexing factors may disturb its measurement, FeNO is widely used in the management of asthmatic children and seems to provide a comparable diagnostic accuracy than spirogram or bronchial challenge tests [10, 24] . The role of FeNO in respiratory infection such as CAP or HAP, viral bronchiolitis, or in cases with diffuse lung disease is less clear [6] .
In the current study, the mean age was higher in HAP and CAP groups, at ∼9 years, which is the age group most associated with increased exposure to outdoor infections. However, VAP presented in 8-year-old children, whereas the last tailed group AsP prevailed in 7-year-old children, which often increase in incidence in younger age groups. In the present study, the outcome was favorable, as survival rate exceeded 90% in research groups. Mortality rate was higher in VAP cases followed by AsP and tailed by CAP owing to the more hazardous effect of ventilator on lung parenchyma, in addition to mixed infectious agents involved in this process. However, injurious effects of anerobic infection and high prevalence of Klebsiella and gram-negative pathogens permit the more lethal consequence for AsP in childhood age group. In the current studied patients, FeNO level did not significantly vary with sex or radiological grades. The results of FeNO level and its affection with sex were previously investigated with conflicting results; some previous researchers found that males have much higher basal FeNO level than females [25, 26] , whereas others found sex does not affect FeNO level [10, 27] . FeNO level was elevated in survived patients in comparison with deceased patients, but without statistically significant differences. FeNO level was significantly affected with modified PIRO score, showing direct proportional rise with increment of the score.
The review of literatures on alteration in FeNO level during CAP in children is scarce. As NO represents portion of the airway inflammatory reaction, its level is anticipated to rise in pneumonia. Even, Kovesi and Dales [28] observed that healthy children with an abnormally high FeNO level had significant positive past history of pneumonia attack in the year proceeding assessment of their FeNO level. Our work stated that FeNO level showed that higher mean values in exhaled air were detected in VAP followed by AsP then HAP and lastly CAP (37.6, 33.4, 31.9, and 29.1 ppb, respectively), with statistically significant differences among the four groups. This variation could be attributed to the different types of microbial affection, which was challenging to be assessed in our work, owing to high prevalence of mixed infection in cultures obtained in the preliminary studied patients, in addition to delayed pursuing of medical advice among these cases in our era. Moreover, the degree of expiratory flow might be more efficient by calibration syringe used in ventilation in comparison with patient effort. In our work, linear regression between FeNO level in the four studied groups and different clinical, laboratory and radiological data was accomplished, which showed a statistically significant weak positive effect of modified PIRO score on FeNO level; this was unlike other factors that showed nonsignificant correlations or effects on FeNO level. The degree of pulmonary involvement and severity of affection was much more matched among cases.
Repetition of the FeNO estimation by our device could not be applied due to limited number of allowed trials to be conducted owing to high cost of device standardization, which was identified as one of study limitations. Unlike our study, Carraro and colleagues performed multiple measurements of FeNO level in children with CAP over 30 days and repeated the measurements after complete resolution of pneumonia to detect their baseline level. They also compared their readings with the healthy individuals, who were age and sex matched. They observed that FeNO levels in children during pneumonia attack did not significantly differ from the control group or from the baseline levels during the follow-up [29] . Different assumptions might clarify this paradox. First, NO yield from expiratory phase is derived from the diffusion of NO in the airways, and therefore at higher flow rates, higher NO will be obtained from samples from the deeper parts of the lung. Second, oxygen radicles may react quickly with the exhaled NO, producing NO metabolites [6] .In a study conducted by Kwak et al. [7] , all the enrolled patients in the study were aged more than 18 years and were mechanically ventilated. They assessed FeNO level in patients with VAP and compared their readings with patients on mechanical ventilation but did not have VAP. They measured FeNO level in collected air from the end-expiratory phase through an off-line method. They noticed that the level of FeNO in the VAP-patients was statistically higher than in the non-VAP group (55.8 vs. 31.8 ppb). Moreover, the higher the FeNO level, the worse the patient prognosis [7] .
In pneumonia, NO level is expected to rise than normal basal level in healthy individuals as toxins secreted from the invading bacteria or their cytokines in the body stimulate vascular endothelial cells to induce NO synthase and activate the enzyme [30, 31] . This is why FeNO is interconnected with the expression of NO synthase in alveolar macrophages; it represents the degree of irritation and inflammation of the airway.
Some investigators believe that this phenomenon is owing to hypoxia, extreme secretion of endothelial cell function, and abnormalities in the airways, hence affect the diffusion of NO [32] . The precise mechanism has not been elucidated yet.
Many limitations were recognized in our study starting from culture taking, computed chest tomography for more localization, repeated estimation of FeNO level, and bronchial challenge assessment to exclude overlapping asthma elements in the studied patients; hence, more detailed upcoming research studies should be carried out on a larger number of patients before universally applying these results.
Conclusion
Measurement of FeNO level in exhaled breath may stand as an acceptable substitute for laboratory blood markers of inflammation side by side in patients with pneumonia. FeNO could be used as a beneficial airway inflammatory marker that is related to modified PIRO score in children but cannot identify pneumonia type. Further studies should be conducted to ascertain these findings.
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